This is an updated version of the report published on January 19, 2026, at 10:23 AM GMT

Spire Healthcare Group PLC (LSE: SPI) 

Spire Healthcare Group PLC (LSE: SPI) is a UK-based company listed at FTSE 250, managing private hospitals and clinics. The organization offers diverse healthcare services, including treatment for allergies, infectious diseases, cancer diagnostics, and cosmetic and general surgeries. It also specializes in areas like cardiology, neurology, pediatrics, and dental care. Additionally, Spire provides diagnostic services such as CT scans, MRI scans, ultrasounds, and X-rays to enhance patient care.

Key Recommendation Rationale – Speculative Buy at GBX 177.20

• Robust Operational Performance and Revenue Growth: Spire has demonstrated resilient revenue growth of despite inflationary pressures and higher National Minimum Wage/NI contributions. The company’s transformation programme, including the launch of Patient Support Centres (PSCs), is already delivering efficiency gains and positions the business for continued operational improvement.
• Strategic Actions to Unlock Shareholder Value: The company is actively exploring options to enhance long-term shareholder returns, including potential hospital property monetisation, private-pay focus, and strategic sale opportunities. These initiatives, combined with operational improvements, provide multiple avenues for value creation beyond organic growth.
• Growth in Self-Pay, PMI, and Primary Care Segments: Self-pay trends are improving, and PMI performance is stable, supported by operational maturity of PSCs. Expansion in Primary Care, including new outpatient clinics and bolt-on M&A, enhances patient referral flows to hospitals and strengthens long-term revenue growth potential. 

Risk Analysis

• NHS Volume and Policy Risk: A significant portion of Spire’s business interacts with the NHS. Slowdowns in NHS commissioning activity due to Integrated Care Board budgetary restrictions, coupled with proposed tariff uplifts below inflation, could limit revenue growth from NHS referrals and create near-term uncertainty.
• Financial and Credit Risk: While the company has extended its debt facilities, adverse changes in interest rates, refinancing conditions, or covenant compliance could affect financial flexibility. Delays in achieving expected savings or EBITDA targets could heighten leverage risk.

Valuation Methodology: Price/ Earnings Approach

Share Price Chart  

 SPI Daily Technical Chart, Source – Refinitiv 

Conclusion

For conducting the valuation, the following peers have been considered - Advanced Medical Solutions Group PLC (LSE: AMS), Smith & Nephew PLC (LSE: SN.), and others.

Given its current trading levels, revenue growth, robust operational performance, positive outlook, relative valuation, and associated risks a ‘Speculative Buy’ recommendation is given on the stock at the Current Market Price of GBX 177.20 as of 19^th January 2026 at 08:30 AM GMT.

Note 1: Past performance is not a reliable indicator of future performance.

Note 2: The reference date for all price data, currency, technical indicators, support, and resistance levels is 19 January 2026. The reference data in this report has been partly sourced from REFINITIV.

Note 3: Investment decisions should be made depending on an individual's appetite for upside potential, risks, holding duration, and any previous holdings. An 'Exit' from the stock can be considered if the Target Price mentioned as per the Valuation and or the technical levels provided has been achieved and is subject to the factors discussed above.

Note 4: Target Price refers to a price level which the stock is expected to reach as per the relative valuation method and/or technical analysis taking into consideration both short-term and long-term scenario.

Note 5: ‘Kalkine reports are prepared based on the stock prices captured either from the London Stock Exchange (LSE) and/or REFINITIV. Typically, both sources (LSE and or REFINITIV) may reflect stock prices with a delay which could be a lag of 15-20 minutes. There can be no assurance that future results or events will be consistent with the information provided in the report. The information is subject to change without any prior notice.’

Note 6: Dividend Yield may vary as per the stock price movement.